Changes in signaling pathways induced by vandetanib in a human medullary thyroid carcinoma model, as analyzed by reverse phase protein array

Thyroid

Volumn 24, Issue 1, 2014, Pages 43-51

  Broutin, Sophie ^a   Commo, Frédéric ^b   De Koning, Leanne ^c   Marty Prouvost, Bérengère ^c   Lacroix, Ludovic ^d   Talbot, Monique ^a   Caillou, Bernard ^d   Dubois, Thierry ^c   Ryan, Anderson J ^e   Dupuy, Corinne ^a   Schlumberger, Martin ^a,d   Bidart, Jean Michel ^a,d  

^a Gustave Roussy Comprehensive Cancer Institute   (France)

^b INSERM   (France)

^c INSTITUT CURIE   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B KINASE ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PLACEBO; PROTEIN KINASE B; PROTEIN RET; S6 KINASE; STAT3 PROTEIN; TRANSCRIPTION FACTOR RELA; VANDETANIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL CULTURE; CANCER GROWTH; CANCER MODEL; CELL VIABILITY; CONTROLLED STUDY; DRUG SCREENING; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTERMETHOD COMPARISON; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; REVERSE PHASE PROTEIN ARRAY; SIGNAL TRANSDUCTION; THYROID MEDULLARY CARCINOMA; TUMOR XENOGRAFT; VALIDATION STUDY; WESTERN BLOTTING;

ADULT; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; PIPERIDINES; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 84892186166     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2013.0514     Document Type: Article

References (39)

1. Leboulleux S, Baudin E, Travagli JP, Schlumberger M 2004 Medullary thyroid carcinoma. Clin Endocrinol (Oxf) 61:299-310
2. Kouvaraki MA, Shapiro SE, Perrier ND, Cote GJ, Gagel RF, Hoff AO, Sherman SI, Lee JE, Evans DB 2005 RET protooncogene: A review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15:531-544
3. Santoro M, Melillo RM, Carlomagno F, Vecchio G, Fusco A 2004 Minireview: RET: Normal and abnormal functions. Endocrinology 145:5448-5451
4. Roman S, Lin R, Sosa JA 2006 Prognosis of medullary thyroid carcinoma: Demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107:2134-2142
5. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA Jr 2009 Medullary thyroid cancer: Management guidelines of the American Thyroid Association. Thyroid 19:565-612
6. Schlumberger M, Carlomagno F, Baudin E, Bidart JM, Santoro M 2008 New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab 4:22-32
7. de Groot JW, Links TP, Plukker JT, Lips CJ, Hofstra RM 2006 RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 27:535-560
8. Arighi E, Borrello MG, Sariola H 2005 RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev 16:441-467
9. Sherman SI 2009 Tyrosine kinase inhibitors and the thyroid. Best Pract Res Clin Endocrinol Metab 23:713-722
10. Wells SA Jr, Santoro M 2009 Targeting the RET pathway in thyroid cancer. Clin Cancer Res 15:7119-7123
11. Bianco R, Rosa R, Damiano V, Daniele G, Gelardi T, Garofalo S, Tarallo V, De Falco S, Melisi D, Benelli R, Albini A, Ryan A, Ciardiello F, Tortora G 2008 Vascular endothelial growth factor receptor-1 contributes to resistance to antiepidermal growth factor receptor drugs in human cancer cells. Clin Cancer Res 14:5069-5080
12. Ciardiello F, Caputo R, Damiano V, Caputo R, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR, Tortora G 2003 Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 9:1546-1556
13. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF 2002 ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62:4645-4655
14. Vitagliano D, De Falco V, Tamburrino A, Coluzzi S, Troncone G, Chiappetta G, Ciardiello F, Tortora G, Fagin JA, Ryan AJ, Carlomagno F, Santoro M 2010 The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Endocr Relat Cancer 18:1-11
15. Verbeek HH, Alves MM, de Groot JW, Osinga J, Plukker JT, Links TP, Hofstra RM 2011 The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. J Clin Endocrinol Metab 96:E991-E995
16. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A, Santoro M 2002 ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62:7284-7290
17. Johanson V, Ahlman H, Bernhardt P, Jansson S, Kolby L, Persson F, Stenman G, Sward C, Wangberg B, Stridsberg M, Nilsson O 2007 A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis. Endocr Relat Cancer 14:433-444
18. Vidal M, Wells S, Ryan A, Cagan R 2005 ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. Cancer Res 65:3538-3541
19. Mueller C, Liotta LA, Espina V 2010 Reverse phase protein microarrays advance to use in clinical trials. Mol Oncol 4:461-481
20. Marty B, Maire V, Gravier E, Rigaill G, Vincent-Salomon A, Kappler M, Lebigot I, Djelti F, Tourdes A, Gestraud P, Hupe P, Barillot E, Cruzalegui F, Tucker GC, Stern MH, Thiery JP, Hickman JA, Dubois T 2008 Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res 10:R101
21. Cleator S, Heller W, Coombes RC 2007 Triple-negative breast cancer: Therapeutic options. Lancet Oncol 8:235-244
22. Levin VA, Panchabhai SC, Shen L, Kornblau SM, Qiu Y, Baggerly KA 2010 Different changes in protein and phosphoprotein levels result from serum starvation of high-grade glioma and adenocarcinoma cell lines. J Proteome Res 9:179-191
23. Rodriguez-Pinilla SM, Sarrio D, Moreno-Bueno G, Rodriguez-Gil Y, Martinez MA, Hernandez L, Hardisson D, Reis-Filho JS, Palacios J 2007 Sox2: A possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol 20:474-481
24. Broutin S, Ameur N, Lacroix L, Robert T, Petit B, Oumata N, Talbot M, Caillou B, Schlumberger M, Dupuy C, Bidart JM 2011 Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models. Clin Cancer Res 17:2044-2054
25. Akeno-Stuart N, Croyle M, Knauf JA, Malaguarnera R, Vitagliano D, Santoro M, Stephan C, Grosios K, Wartmann M, Cozens R, Caravatti G, Fabbro D, Lane HA, Fagin JA 2007 The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res 67:6956-6964
26. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, Santoro M 2006 BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98:326-334
27. Speer R, Wulfkuhle J, Espina V, Aurajo R, Edmiston KH, Liotta LA, Petricoin EF, 3rd 2008 Molecular network analysis using reverse phase protein microarrays for patient tailored therapy. Adv Exp Med Biol 610:177-186
28. Gorla L, Mondellini P, Cuccuru G, Micciche F, Cassinelli G, Cremona M, Pierotti MA, Lanzi C, Bongarzone I 2009 Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: Identification of new signaling elements. Mol Carcinog 48:220-231
29. Jane EP, Premkumar DR, Addo-Yobo SO, Pollack IF 2009 Abrogation of mitogen-Activated protein kinase and Akt signaling by vandetanib synergistically potentiates histone deacetylase inhibitor-induced apoptosis in human glioma cells. J Pharmacol Exp Ther 331:327-337
30. Sarkar S, Mazumdar A, Dash R, Sarkar D, Fisher PB, Mandal M 2010 ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells. Cancer Biol Ther 9:592-603
31. Wu W, Onn A, Isobe T, Itasaka S, Langley RR, Shitani T, Shibuya K, Komaki R, Ryan AJ, Fidler IJ, Herbst RS, O'Reilly MS 2007 Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther 6:471-483
32. Li QQ, Chen ZQ, Cao XX, Xu JD, Xu JW, Chen YY, Wang WJ, Chen Q, Tang F, Liu XP, Xu ZD 2011 Involvement of NF-kappaB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial-mesenchymal transition of breast cancer cells. Cell Death Differ 18:16-25
33. Veeraraghavan J, Natarajan M, Aravindan S, Herman TS, Aravindan N 2011 Radiation-Triggered tumor necrosis factor (TNF) a-NFjB cross-signaling favors survival advantage in human neuroblastoma cells. J Biol Chem 286:21588-21600
34. Pacifico F, Leonardi A 2010 Role of NF-kappaB in thyroid cancer. Mol Cell Endocrinol 321:29-35
35. Mitsiades CS, McMillin D, Kotoula V, Poulaki V, McMullan C, Negri J, Fanourakis G, Tseleni-Balafouta S, Ain KB, Mitsiades N 2006 Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J Clin Endocrinol Metab 91:4013-4021
36. Rapa I, Saggiorato E, Giachino D, Palestini N, Orlandi F, Papotti M, Volante M 2011 Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma. J Clin Endocrinol Metab. 96:2146-2153
37. Tamburrino A 2011 Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases ASCO meeting. Chicago: Abstract no. 10598
38. Holland WS, Tepper CG, Pietri JE, Chinn DC, Gandara DR, Mack PC, Lara PN Jr 2011 Evaluating rational non-crossresistant combination therapy in advanced clear cell renal cell carcinoma: Combined mTOR and AKT inhibitor therapy. Cancer Chemother Pharmacol. 69:185-194
39. Yang Y, Ikezoe T, Nishioka C, Taguchi T, Zhu WG, Koeffler HP, Taguchi H 2006 ZD6474 induces growth arrest and apoptosis of GIST-T1 cells, which is enhanced by concomitant use of sunitinib. Cancer Sci 97:1404-1409